India, June 23 -- IMUNON, Inc. (IMNN) announced that an independent Data Monitoring Committee has recommended the continuation of the pivotal Phase 3 OVATION 3 trial without any changes, following a scheduled interim safety and efficacy review.
The decision reinforces confidence in the company's DNA-based immunotherapy, IMNN-001, for women with newly diagnosed advanced ovarian cancer.
Ovarian cancer is often diagnosed at an advanced stage, where recurrence rates are high and long-term survival remains limited. IMUNON is developing IMNN-001 as a localized immunotherapy designed to activate the immune system directly within the tumor environment.
Phase 3 OVATION 3 Trial Overview
The Phase 3 OVATION 3 study is evaluating IMNN-001 in combin...